We are pleased to welcome Dr. Barbara McGovern,MD to the C Diff Foundation. Dr. McGovern presides as a member of the Foundation’s Medical Advisory Board.
Dr. Barbara McGovern is Vice President of Medical Affairs at Seres Therapeutics. She obtained her M.D. degree from the Albert Einstein College of Medicine and did her residency and infectious disease training at Tufts Medical Center where she worked many years as an infectious disease specialist.
Her clinical career began in working with HIV-infected patients, including taking care of incarcerated women with HIV and hepatitis C co-infection. When the rates of morbidity and mortality from HIV declined on potent ant-iretroviral therapy, she was one of the first to observe that end-stage liver disease secondary to hepatitis C infection had become a leading cause of death in HIV-infected patients and subsequently devoted her clinical research career to the management of these patients.
Dr. McGovern served as a member of the Antiviral Advisory Committee for the U.S. Food and Drug Administration (FDA) and also served several years on the Department of Health and Human Services Guideline Committee for management of viral hepatitis in HIV-infected patients. Dr. McGovern was also an Associate Editor at Clinical Infectious Diseases and was a Deputy Editor at Up-To-Date, an international medical journal where she founded a Global Health section for the care of patients living in developing countries.
Over the past three years she started working within the pharmaceutical arena and is currently head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a Phase 2 clinical trial for recurrent Clostridium difficile infection.
Join us at 10 a.m. Pacific Time, 11 a.m. Mountain Time, 12 p.m. Central Time,
and 1 p.m. Eastern Time.
with our two guests:
Dr. Caterina Oneto, MD – a Clinical Assistant Professor within the NYU Division of Gastroenterology, Board Certified in Gastroenterology and Internal Medicine.
Fluent in Spanish, she graduated with a degree in Medicine and Surgery from the
Universidad de Valparaiso in Chile. She completed her residency in
Internal Medicine at Cabrini Medical Center, where she served also as Chief Resident, and later completed her Fellowship in Gastroenterology at Montefiore Medical Center, Albert Einstein College of Medicine. With expertise in endoscopy, colonoscopy, capsule endoscopy, liver and pancreatic diseases, Dr. Oneto’s special interests include IBD (Crohn’s disease and Ulcerative Colitis), IBS (irritable bowel syndrome), microbiota modification, treatment of Clostridium Difficile and FMT (Fecal Microbiota Transplantation).
Dr. Paul Feuerstadt, MD – A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude. Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, New York for his clinical fellowship training.
Throughout Dr. Feuerstadt’s training and practice he has been actively involved in research and other academic pursuits. His areas of interest include ischemic diseases of the gut and chronic diarrheal syndromes with a specific focus on Clostridium difficile infection. He has presented his research extensively at national meetings and has authored and co-authored many manuscripts and textbook chapters. Another passion of Dr. Feuerstadt’s is teaching, frequently mentoring the fellows in the Division of Digestive Disease at Yale-New Haven Hospital where he holds a clinical appointment as a Clinical Instructor of Medicine. His clinical practice is his ultimate passion filling the majority of his work time seeing a broad spectrum of patients with gastrointestinal and hepatic disease. Dr. Feuerstadt is affiliated with the
St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital seeing outpatients in his offices in Hamden and Milford, Connecticut.
* All “C. diff. Spores and More ” episodes and archived programs are available on demand by accessing the following link:
Hard Facts: Deaths and illnesses are much higher than reports have shown. Nearly half a million Americans suffered from Clostridium difficile (C. diff.) infections in a single year according to a study released today, February 25, 2015, by the Centers for Disease Control and Prevention (CDC).
• More than 100,000 of these infections developed among residents of U.S. nursing homes.
Approximately 29,000 patients died within 30 days of the initial diagnosis of a C. diff. infection. Of these 29,000 – 15,000 deaths were estimated to be directly related to a C. diff. infection. Therefore; C. diff. is an important cause of infectious disease death in the U.S.
Previous studies indicate that C. diff. has become the most common microbial cause of Healthcare-Associated Infections found in U.S. hospitals driving up costs to $4.8 billion each year in excess health care costs in acute care facilities alone. Approximately
two-thirds of C. diff. infections were found to be associated with an inpatient stay in a health care facility, only 24% of the total cases occurred in patients while they were hospitalized. The study also revealed that almost as many cases occurred in nursing homes as in hospitals and the remainder of individuals acquired the
Healthcare-Associated infection, C. diff., recently discharged from a health care facility.
This new study finds that 1 out of every 5 patients with the Healthcare-Associated Infection (HAI), C. diff., experience a recurrence of the infection and 1 out of every 9 patients over the age of 65 diagnosed with a HAI – C. diff. infection died within 30 days of being diagnosed. Older Americans are quite vulnerable to this life-threatening diarrhea infection. The CDC study also found that women and Caucasian individuals are at an increased risk of acquiring a C. diff. infection. The CDC Director, Dr. Tom Frieden, MD, MPH said, “C. difficile infections cause immense suffering and death for thousands of Americans each year.” “These infections can be prevented by improving antibiotic prescribing and by improving infection control in the health care system. CDC hopes to ramp up prevention of this deadly infection by supporting State Antibiotic Resistance Prevention Programs in all 50 states.”
“This does not include the number of C. diff. infections taking place and being treated in other countries.” “The C Diff Foundation supports hundreds of communities worldwide by sharing the Foundation’s mission and raising C. diff. awareness with healthcare professionals, individuals, patients, families, and communities working towards a shared goal ~ witnessing a reduction of newly diagnosed C. diff. cases by 2020 .” ” The C Diff Foundation volunteer Advocates are greatly appreciated and continue to create positive changes by sharing their time aiding in the success of our mission “Raising C. diff. awareness ” worldwide.
“C. diff. Spores and More “ spotlights world renowned topic experts, research scientists, healthcare professionals, organization representatives, C. diff. survivors, board members, and their volunteers who are all creating positive changes in the
C. diff. community and more.
Through their interviews, the C Diff Foundation mission will connect, educate, and empower many worldwide.
Questions received through the show page portal will be reviewed and addressed by the show’s Medical Correspondent, Dr. Fred Zar, MD, FACP, Dr. Fred Zar is a Professor of Clinical Medicine, Vice Head for Education in the Department of Medicine, and Program Director of the Internal Medicine Residency at the University of Illinois at Chicago. Over the last two decades he has been a pioneer in the study of the treatment of Clostridium difficile disease and the need to stratify patients by disease severity.
Join us and listen in beginning January 19th, 2016 on Tuesdays for educational episodes of “C. diff. Spores and More”
View the programs and radio information by clicking on the link below:
Programming for C. diff. Spores and More is made possible through our official Corporate Sponsor; Clorox Healthcare